Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with relapsed and/or refractory myeloma who have received between 1-4 prior lines of therapy~* Must have adequate liver and renal function~* Zubrod Performance Status (ZPS) of 2 or better~* Must have measurable disease~Exclusion Criteria:~* Peripheral neuropathy of grade II or higher~* Thrombocytopenia (platelets less than 50,000/uL)~* Neutropenia (ANC\<1000/uL)~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.4 X ULN~* Total bilirubin \>1.5 X upper limit of normal (ULN)~* Creatinine clearance of less than 45 milliliters per minute (mL/min)~* Patients with HIV~* Patients with active hepatitis~* Pregnant or lactating women~* Individuals of child-bearing potential not using adequate contraception~* Individuals unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bendamustine (Type: EXPERIMENTAL): Bendamustine is combined with standard chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).